You are about to leave the Clinical Value website now.



Lung Cancer

Lung cancer is one of the most common forms of cancer, with 1.3 million people being diagnosed every year in APAC. Majority of these cases are diagnosed at late stages, when survival rates are low.

Pan Cancer

Cancer is the leading cause of death worldwide, responsible for nearly 1 in 6 deaths in 2020, majority of which coming from Asia. With an ageing population, and emerging factors like diet and environment, the burden of cancer is only projected to increase.

Liver Cancer

Known also as the silent killer, chronic liver disease is big, complex and accelerating. Driven by viral infection, diet and lifestyle, 1.5 billion people worldwide are in jeopardy. Of these, 80% of new cases and 72% of total deaths occur in Asia alone.

Cervical Cancer

Cervical cancer has a high disease burden in APAC, with 50% of global cases and 60% of global deaths occuring in APAC. Almost all (99%) cervical cancer cases are linked to infection with high risk human papillomavirus, which is easily preventable through vaccination, advances in screening, and appropriate treatment. However, barriers still exist that prevent some women from being screened for cervical cancer.

Recent Articles

14 June 2024

Empowering Healthcare Professionals to Combat Liver Cancer in Australia

2 October 2023

Patient-centric and ecosystem insights into hepatocellular carcinoma across Asia-Pacific – LEAP

In this white paper, insights on the liver ecosystem are uncovered, with the intention of facilitating action among various stakeholders to reduce liver cancer incidence and…

23 August 2023

Building modern hepatocellular carcinoma surveillance programmes: taking steps to address a leading cause of liver cancer death in Asia

In this whitepaper, HCC surveillance programs in Asia were analysed. The learnings from well established HCC surveillance programs, as well as the challenges in areas that…

14 March 2023

International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma

This white paper, which was developed by a group of experts in biomarker development, provides a framework on best practices to design, execute, and interpret biomarker…

9 December 2022

Liver Disease in Asia Pacific: Insights from Prof Pierce Chow

In this Q&A, Prof Pierce Chow of the National Cancer Centre Singapore discusses the epidemiology of liver disease in Asia Pacific; key considerations around the clinical…

9 December 2022

Liver Cancer in Japan: Dr Shun Kaneko on HCC Screening and Surveillance

Japan is a global leader in hepatocellular carcinoma (HCC) surveillance, with an effective programme that enables early-stage carcinomas detection. Yet unmet needs continue to affect the…

9 December 2022

Strengthening healthcare systems through the critical role of diagnostics

In line with the WHO Essential Diagnostics List (EDL) and Lancet Commission efforts, the Asia Pacific Medical Technology Association and its members recently came together to…

9 December 2022

APACMed White Paper – Strengthening Healthcare Systems Through the Critical Role of Diagnostics

Diagnostic technologies are used across the entire patient journey of multiple disease states, and provide the tools to prevent, detect, and monitor the required interventions. Despite…


Be the first to receive updates, event opportunities, and thought leadership insights.